MIT Analysts Give Economic Arguments For Retaining PMA Preemption
This article was originally published in The Gray Sheet
Executive Summary
Eliminating federal preemption protection for FDA-approved medical devices would likely result in industry employment losses and increased government expenses, two experts from MIT's Sloan School of Management predict